Učitavanje...
Chemoprevention of Hormone Receptor-Negative Breast Cancer: New Approaches Needed
Results from clinical trials have demonstrated that it is possible to prevent estrogen-responsive breast cancers by targeting the estrogen receptor with selective estrogen receptor modulators (SERMs) (tamoxifen, raloxifene, or lasofoxifene) or with aromatase inhibitors (AIs) (anastrozole, letrozole,...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3415693/ https://ncbi.nlm.nih.gov/pubmed/21253797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/978-3-642-10858-7_13 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|